Allogeneic Mesenchymal Stem Cells for Inflammaging-Linked Frailty

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Aging frailty and non-ischemic dilated cardiomyopathy are characterized by immune dysregulation and chronic inflammation, with no effective treatments available, and allogeneic mesenchymal stem cells have shown mixed effects on the immune system, including suppression of B cell function and T cell proliferation.

Innovation Solution

Administering a therapeutically effective amount of isolated allogeneic human mesenchymal stem cells to subjects, targeting specific biomarkers such as exhausted B cells, switched memory B cells, and inflammatory cytokines to modulate the immune response and improve immune function.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Object-affected harmful factors

If allogeneic mesenchymal stem cells are administered to treat aging frailty and immune dysregulation, then inflammatory cytokines are reduced and immune function is improved, but the cells may suppress B cell function and T cell proliferation

Engineering Contradiction:

Improveinflammatory cytokinesVSAvoidimmune function

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

The patent changes the parameters of the mesenchymal stem cells by selecting for specific surface marker profiles (CD73+, CD90+, CD105+, CD45-, CD34-) to identify a subpopulation with optimal immunomodulatory properties while minimizing suppressive effects on immune cell function

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent applies local quality by targeting specific immune cell populations with different effects - reducing inflammatory cytokines and exhausted B cells while preserving or enhancing switched memory B cells and CD4+ T cells, creating a differentiated immunomodulatory response rather than uniform suppression

Inventive Principle:

Principle #3Local quality

2Object-affected harmful factors

If mesenchymal stem cells are used to reduce exhausted B cells and chronic activated T cells, then inflammation is reduced, but the ability to maintain protective immunity may be compromised

Engineering Contradiction:

Improveexhausted B cells and chronic activated T cellsVSAvoidprotective immunity

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

The patent changes the parameters by selecting mesenchymal stem cells with specific surface marker profiles that correlate with enhanced ability to modulate exhausted and chronically activated immune cells while preserving protective immune responses

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent applies partial action by selectively reducing only the pathogenic subsets of B cells (exhausted, CD27-) and T cells (chronically activated, CD25+) while maintaining or enhancing protective immune cell populations (switched memory B cells, CD4+ T cells), rather than suppressing all immune cell activity

Inventive Principle:

Principle #16Partial or excessive action

Data Source

PatentUS12465620B2Method of treating aging frailty in subjects with inflammaging using human mesenchymal stem cells

Publication Date: 2025.11.11 LONGEVERON INC

AI summary

The present invention provides a method of treating subjects with non-ischemic dilated cardiomyopathy by administering a therapeutically effective amount of an isolated population of allogeneic human mesenchymal stem cells. The present invention also provides a method of treating subjects with symptoms of aging frailty by administering a therapeutically effective amount of an isolated population of allogeneic human mesenchymal stem cells.